Products

PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer

    • Product Name: PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: admin@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    Specifications
    HS Code 665383
    Productname PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer
    Manufacturer Corbion (Purac Biomaterials)
    Productcode PLG 8055
    Chemicalname Poly(L-lactide-co-glycolide)
    Synonym PLGA 80:20; Poly(L-lactide-co-glycolide) 80:20
    Casnumber 57342-11-3
    Monomerratio 80:20 (L-lactide:glycolide, mol/mol)
    Monomercomposition 80 mol% L-lactide; 20 mol% glycolide
    Inherentviscosity 5.5 dL/g nominal (typical range 5.0–6.0 dL/g; chloroform, 30°C)
    Appearance White to off-white granules
    Physicalform Granules/pellets
    Density 1.2–1.4 g/cm³ (typical)
    Glasstransitiontemperature 50–60°C (typical)
    Solubility Soluble in chloroform, dichloromethane, hexafluoroisopropanol; insoluble in water and ethanol
    Residualmonomercontent < 0.5%
    Moisturecontent < 0.5%
    Heavymetals < 10 ppm
    Storageconditions Store at -20°C, protected from moisture, in a sealed container
    Shelflife 2 years (typical)
    Sterilizationcompatibility Gamma irradiation, ethylene oxide
    Degradationproducts Lactic acid and glycolic acid
    Medicaldevicegrade Yes
    Biocompatibility USP Class VI, ISO 10993 tested
    Regulatorycompliance Manufactured under ISO 13485 and GMP

    As an accredited PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer, 1 kg, supplied in a sealed aluminum foil bag.
    Container Loading (20′ FCL) PURASORB PLG 8055 loaded in a clean, dry 20′ FCL: sealed, labeled packages palletized, moisture-controlled, and secured for ocean transport.
    Shipping PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer is shipped as a non-hazardous solid. It is not regulated for transport, with no UN number, hazard class, or packing group. Use sealed, moisture-barrier packaging; keep dry, cool, and protected from heat and light. No dangerous goods documentation required.
    Storage Store the copolymer in its original, tightly sealed, moisture-proof container in a cool, dry, well-ventilated area, preferably refrigerated at 2–8 °C. Protect from heat, light, moisture, and oxidizing agents. Allow to equilibrate to room temperature before opening to prevent condensation. Avoid repeated temperature fluctuations and prolonged air exposure. Keep container closed when not in use. Follow the manufacturer’s storage instructions.
    Shelf Life PURASORB PLG 8055 has a two-year shelf life from manufacture when stored unopened at -20°C, protected from moisture.
    Application of PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer

    For braided absorbable suture lines, PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer is processed as the load-bearing multifilament yarn and is not diluted with plasticizer; the core yarns consist of 100 wt% polymer, while an optional absorbable surface coating of polycaprolactone and calcium stearate is applied at 2–5 wt% of total suture mass to reduce tissue drag and knot chatter. Melt spinning is carried out on a single-screw extruder with a 24:1 L/D screw, barrel zones maintained at 170–200°C, and a multi-hole spinneret with individual capillary diameters below 1.0 mm; extrusion draw ratio is maintained at 4–7× before annealing at 80–120°C for 1–4 h to stabilize dimensional recovery. Compliance for this device category is anchored to ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-10:2010, ISO 10993-11:2017, ISO 10993-6:2016, FDA 21 CFR 878.4490, and ISO 13485:2016; material characterization before yarn extrusion follows ISO 13781:2017 and ASTM F1635-16. Finished product types include braided absorbable sutures in USP sizes 2–6/0 for general soft tissue approximation and vessel ligation, where the 80:20 L-lactide-to-glycolide ratio and nominal inherent viscosity midpoint of 0.55 dL/g provide a degradation profile slower than 50:50 PLGA but faster than 85:15 PLGA. The primary processing boundary is melt residence time: total barrel residence above 5 min promotes transesterification and shifts molar mass distribution, producing weak braided yarn; batch changeover procedures must therefore specify purge intervals validated by ISO 1133-1:2022 melt flow-rate testing and melt pressure monitoring at the breaker plate.

    What Encapsulation Efficiency Limits Arise During Aseptic Oil-in-Water Solvent Evaporation?

    Injectable microsphere depot processing with PLG 8055 is governed by organic-phase polymer concentration, continuous-phase viscosity, and solvent removal rate; the established formulation window uses PLG 8055 dissolved in dichloromethane at 10–30 wt%, drug loading between 5–50 wt% relative to polymer mass, an oil-to-water phase ratio of 1:8–1:20, and poly(vinyl alcohol) at 0.5–2.0 wt% in the aqueous continuous phase. Production-scale emulsification typically uses an in-line rotor-stator homogenizer with tip speeds of 10–20 m/s, followed by solvent extraction into excess water at 4–25°C and lyophilization; lyoprotectant addition of mannitol at 2–5 wt% of the total final suspension prevents irreversible aggregation of microspheres during vial freezing. Regulatory and quality compliance for sterile injectable microsphere products requires USP <71> sterility testing, USP <85> bacterial endotoxin limits, USP <788> subvisible particulate matter, ICH Q3C(R8) residual solvent limits with dichloromethane below 600 ppm and chloroform below 60 ppm, EU GMP Annex 1 aseptic processing, and ISO 10993-1:2018 biological evaluation when the microsphere is part of a combination product or medical device. Finished terminal dosage forms include intramuscular and subcutaneous long-acting depots for peptide and small-molecule active pharmaceutical ingredients; for acid-labile peptides, internal pH decline to pH 3 or below during PLGA bulk degradation can inactivate the payload, and published formulation literature describes poorly soluble basic additives such as magnesium hydroxide at 1–3 wt% of polymer mass to moderate intraparticle acidity. Encapsulation efficiency above 70% for low-molecular-weight hydrophilic drugs is rarely achieved without osmotic stabilizers or co-solvent adjustments, and lot-to-lot differences in PLG 8055 inherent viscosity alter primary emulsion droplet breakage, so viscosity must be re-normalized per ISO 13781:2017 before scaling. Published data for PLG 8055 paired with a specific peptide payload in this exact configuration is limited; feasibility lots are therefore run at 50 g scale with accelerated stability per ASTM F1635-16 before pilot commitment.

    Injection Moulding Windows for Resorbable Cortical Bone Screws

    Resorbable bone fixation hardware fabricated from PLG 8055 requires melt processing under stringent moisture control; the polymer is either injected neat at 100 wt% or compounded with β-tricalcium phosphate at 10–30 wt% to modulate acid-buffering and modulus. Vacuum drying at 40–50°C for 12–24 h to residual moisture below 250 ppm is mandatory before melt processing. Injection moulding on a 500 kN clamp force machine with a 16 mm screw at 18:1 L/D uses barrel temperatures 170–200°C, mould surface temperatures 20–45°C, injection pressures 80–120 MPa, holding pressures 40–70 MPa, and cooling times 20–40 s; total screw residence time is kept below 5 min to limit lactide regeneration and molecular weight loss. The melt fill pattern in long, thin cortical screw cores exhibits jetting and weld-line weakness when the gate diameter falls below 0.5 mm, so multi-gate or direct edge-gate layouts with runner diameters above 1.0 mm are specified. Compliance is governed by ISO 13781:2017, ASTM F1925-17, ASTM F1635-16, ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, and ISO 10993-11:2017; terminal sterilization commonly uses ethylene oxide per ISO 11135:2014 because gamma irradiation at 25 kGy can reduce inherent viscosity by chain scission, and published data for PLG 8055 electron-beam dose mapping is limited. Finished terminal product types are interference screws, suture anchors, small bone pins, and fracture fixation screws for low-load osteochondral and ligament fixation, but not diaphyseal load-bearing plates unless combined with a reinforcing bioceramic or an oriented self-reinforced laminate. Batch-to-batch variance in melt viscosity must be monitored by capillary rheometry at 190°C and shear rates 100–1000 s-1, because a viscosity shift of more than 10% from the qualification lot alters cavity packing and final part mass.

    Terminal device categoryMaterial characterizationBiological evaluationSterility / aseptic processingQuality system
    Braided absorbable sutureISO 13781:2017, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016
    Injectable microsphere depotISO 13781:2017, ICH Q3C(R8)ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017USP <71>, USP <85>, USP <788>, EU GMP Annex 1ISO 13485:2016
    Resorbable cortical bone screwISO 13781:2017, ASTM F1925-17, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016
    Periodontal barrier membraneISO 13781:2017, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016
    Post-surgical adhesion barrier filmISO 13781:2017, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016
    Fused filament bone void fillerISO 13781:2017, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016
    Resorbable ligating clipISO 13781:2017, ASTM F1925-17, ASTM F1635-16ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017ISO 11135:2014ISO 13485:2016

    Solvent-cast guided tissue regeneration membranes use PLG 8055 as the principal polymer matrix with no plasticizer; the casting solution is prepared at 10–15 wt% polymer in dichloromethane, and sodium chloride sieved to 100–300 µm is dispersed at a 3:1 salt-to-polymer mass ratio to create interconnected pores after leaching. The solution is applied with a doctor blade onto a polyester release liner at a wet film thickness of 300–700 µm, solvent is evaporated under controlled humidity below 40% RH, and the film is washed in deionized water to remove sodium chloride and vacuum-dried to residual solvent below 600 ppm dichloromethane. Biological evaluation is conducted under ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, and ISO 10993-11:2017, with material characterization per ISO 13781:2017 and final device quality under ISO 13485:2016. Terminal finished product types are resorbable periodontal barrier membranes placed over bone defects to prevent epithelial downgrowth, supplied as sterile single-patient envelopes after ethylene oxide sterilization per ISO 11135:2014.

    When Low-Gauge Post-Surgical Barriers Require Controlled In Vivo Film Hydration

    Flat-die cast extrusion of PLG 8055 into bioresorbable adhesion barrier film uses the polymer at 100 wt% without slip agents or plasticizers; extruder barrel temperatures are maintained at 160–190°C, die lip gap is set at 0.15–0.30 mm, and the melt is cast onto a chilled polished roll at 10–25°C to produce a final film thickness of 0.02–0.10 mm after longitudinal slitting. The main processing constraint is moisture-induced viscosity loss during extrusion; resin must be dried to below 250 ppm moisture, and extrusion output must be adjusted so melt pressure remains stable within ±5% to avoid gauge variation that would create thin spots and premature film disintegration. Compliance for this resorbable medical device category is based on ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017, ISO 11607-1:2019 for sterile barrier packaging, and ISO 13485:2016; in vitro hydrolysis mass loss is characterized by ASTM F1635-16. Finished terminal products are resorbable adhesion prevention films for abdominal, pelvic, and peritoneal surgical sites, where the film maintains mechanical separation for a limited number of weeks before bulk erosion. Published data for PLG 8055 cast-film degradation in infected wound environments is limited; therefore, implantation testing per ISO 10993-6:2016 with local infection models may be required when the intended claim includes microbiologically challenged tissue.

    Fused Filament Fabrication of Custom Resorbable Bone Void Fillers

    PLG 8055 filaments for fused filament fabrication are produced by pre-drying resin below 250 ppm moisture, extruding on a single-screw extruder with 24:1 L/D at 160–190°C, and spooling filament at 1.75 mm diameter with roundness tolerance ±0.05 mm; the filament is then printed at nozzle temperatures 150–180°C, bed temperatures 30–50°C, layer heights 0.1–0.2 mm, and infill angles selected to generate pore sizes of 300–500 µm after thermal shrinkage. For osteoconductive scaffolds, PLG 8055 is compounded with hydroxyapatite at 5–20 wt% in a PLG 8055 matrix of 80–95 wt% using a co-rotating twin-screw extruder with 40:1 L/D and a segmented screw including kneading blocks; hydroxyapatite loadings above 20 wt% cause nozzle clogging and layer-to-layer delamination in parts printed without a heated chamber. Mechanical performance is characterized by ASTM D638-14 tensile testing and ASTM D695-15 compressive testing on printed specimens; biological evaluation follows ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, and ISO 10993-11:2017, while degradation testing follows ASTM F1635-16. Terminal finished products are patient-specific craniofacial bone void fillers and alveolar ridge scaffolds requiring resorbability and optional CT-visible filler addition. The main batch-scale bottleneck is filament ovality and moisture pickup during storage; spools must be sealed with desiccant and conditioned below 30% RH before printing, or the printed strand diameter will fluctuate beyond ±5% and distort the final pore geometry.

    Melt-moulded resorbable ligating clips from PLG 8055 are produced as single-use surgical devices in multi-cavity injection moulds with sub-millimetre gate diameters and mould surface temperatures of 25–40°C; the polymer is used at 100 wt% without filler because the clip hinge must maintain a homogeneous amorphous microstructure. Barrel temperatures are set to 180–195°C, and post-mould annealing is performed at 60–80°C for 1–3 h to reduce moulded-in stress that can cause delayed hinge fracture or premature opening during vessel occlusion. The device is tested under ISO 10993-1:2018, ISO 10993-5:2009, ISO 10993-6:2016, ISO 10993-10:2010, ISO 10993-11:2017, ISO 13781:2017, and ASTM F1925-17, with terminal sterilization by ethylene oxide per ISO 11135:2014; residual ethylene oxide and ethylene chlorohydrin limits are controlled per ISO 10993-7:2008. Terminal finished product types are resorbable ligating clips for vascular and cystic duct occlusion, marketed as preloaded cartridge systems or single-piece clips for manual application forceps. Published data for PLG 8055 in this exact ligating clip hinge design is limited; therefore, clip closing force retention after accelerated hydrolysis per ASTM F1635-16 must be established with each new mould configuration before batch release. Injection speed is the dominant variable in avoiding flow marks and brittle hinge failure; filling too slowly below 30 mm/s ram speed solidifies the melt before complete hinge packing, while filling above 60 mm/s can trap gas at the hinge periphery.

    Free Quote

    Competitive PURASORB PLG 8055 Medical Device Lactide-Glycolide Copolymer prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618136850665 or mail to admin@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618136850665

    Email: admin@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    PURASORB PLG 8055 is a medical-grade poly(L-lactide-co-glycolide) supplied as white to off-white granules. The product designation denotes an 80:20 molar ratio of L-lactide to glycolide and a nominal inherent viscosity of 0.55 dL/g determined at 0.1 g/dL in chloroform at 25°C in accordance with ISO 1628-1. The copolymer is produced with predominantly carboxylic acid terminal groups, a structural feature that distinguishes the grade from ester-capped copolymers and influences water uptake, autocatalytic hydrolysis, and early-stage strength-loss behaviour. Under the manufacturer’s batch-release system certified to EN ISO 13485:2016, the certificate of analysis reports monomer ratio by nuclear magnetic resonance, residual monomers and residual solvents by gas chromatography, and water content by Karl Fischer titration, with chemical characterization aligned to ISO 10993-18:2020. The grade is intended for conversion by melt processing into bioresorbable implants such as interference screws, suture anchors, and fracture fixation pins, where the resorption profile must be matched to healing timelines rather than left to generic polylactide behaviour.

    Unopened vacuum-sealed bags are stored at -20°C in a dry environment. Before opening, the bag is equilibrated to ambient temperature for 4–6 h to prevent condensation on cold granulate. Once opened, the contents should be consumed in a single shift or immediately re-purged with dry nitrogen and vacuum-sealed. Differential scanning calorimetry of the dried granulate at a heating rate of 10 K/min under nitrogen typically places the glass transition temperature between 45°C and 55°C. The material is largely amorphous under standard processing conditions, with no pronounced melting endotherm above 100°C when the copolymer sequence is maintained. Residual water in incoming lots is controlled to a maximum of 0.5 wt%. The lot-specific inherent viscosity midpoint is accompanied by an acceptance window of ±0.05 dL/g; longer chains are not obtained by simply combining lots because melt stability varies with residual monomer and moisture history.

    Does Acid Termination Shift the Hydrolytic Degradation Profile When Compared with an Ester-Capped 80:20 Copolymer?

    The terminal group chemistry is not a minor packaging detail in PURASORB PLG 8055. Because the chains end in carboxylic acid moieties rather than ester capping groups, water absorption in the first 72 h of immersion produces a locally lower pH inside the polymer matrix, and this accelerates autocatalytic cleavage of the ester backbone. In contrast, an ester-capped 80:20 copolymer of comparable chain length shows slower initial hydrolysis under the same in vitro conditions. The practical consequence is that devices made from acid-capped PURASORB PLG 8055 reach a given loss of inherent viscosity earlier than an ester-capped equivalent, while the overall mass-loss timeline remains governed by the 80:20 monomer ratio. Published head-to-head data for this exact product lot is limited; comparative evaluations should therefore use specimens of identical surface-area-to-volume ratio, immersion in phosphate-buffered saline at pH 7.4 and 37°C, and periodic analysis per ASTM F1635.

    The monomer ratio sets the longer-term degradation horizon. A 80:20 L-lactide/glycolide copolymer retains mechanical integrity longer than a 50:50 copolymer under identical test conditions because the lower glycolide content reduces hydrophilicity and slows bulk water diffusion. For load-bearing fixation devices that must carry stress for 8–12 weeks, this slower profile is often selected over faster-resorbing 50:50 grades. Retention interval is not determined solely by the copolymer ratio; part thickness, crystallinity, residual monomer, sterilization history, and implantation-site fluid exchange also shift the curve. These variables are controlled through design verification using ASTM F2502 for creep and stress relaxation when load-bearing devices are assessed.

    When Residual Moisture Reaches 0.5 wt%, the Drying Protocol Becomes the Primary Processing Boundary

    PURASORB PLG 8055 is hydrolytically labile at melt-processing temperatures, and the most common production failure is moisture-induced viscosity loss during plastication. If Karl Fischer titration of incoming granulate shows water content above 0.5 wt%, the resin must be dried before any melt-processing trial. Vacuum drying at 45°C under ≤50 mbar for 12–24 h is a defined starting condition; drying is terminated when a sample drawn from the bed reads below 250 ppm moisture by ISO 15512. A hopper dryer with dry nitrogen at a dew point of -40°C or lower may be used for continuous operation, but the hopper residence time at temperatures above 50°C should not exceed 2 h to limit hydrolytic chain scission. If granulate is exposed to ambient air at relative humidity above 60% for more than 15 min, re-drying is required because surface moisture re-adsorbs rapidly onto cold granules.

    Drying uniformity is also a batch-scale problem. In a vacuum tray oven, the granulate bed should not exceed 5 cm depth; deeper beds produce moisture gradients between top and bottom pellets and cause inconsistent melt viscosity in consecutive shots. A rotary vacuum dryer is used for larger lots, with a jacket temperature of 45°C and rotation at 5–10 rpm. If a lot has been exposed to moisture for an extended period, vacuum drying alone may not restore the original inherent viscosity because hydrolytic chain scission has already occurred; disposition is then based on the remaining inherent viscosity measured by ISO 1628-1, not on additional drying time.

    Cold granulate shifted directly from a -20°C freezer to an open feed hopper creates a second moisture barrier: condensation forms on the pellet surface before the material reaches the barrel. The sealed aluminum-laminated bag must be allowed to equilibrate to ambient temperature while still closed, usually for 4–6 h depending on bag mass. This boundary is operational rather than speculative; production sites that skip equilibration often observe intermittent screw feeding, nozzle drool, and a drop in melt viscosity that disappears when Karl Fischer analysis of the hopper feed returns to the 250 ppm limit.

    Melt processing on a reciprocating-screw injection moulding machine with a screw L/D of 20:1 to 25:1 and a general-purpose low-shear metering geometry has been used to convert PURASORB PLG 8055 into small orthopaedic implants. The nozzle melt temperature is maintained between 180°C and 210°C, and the mould is held at 20–40°C. Injection pressures in the range of 80–140 MPa are typical for thin-wall geometries; pack/hold pressure is limited to 50–70% of the injection pressure to avoid overpacking and residual stress. Total residence time in the barrel above 210°C should not exceed 10 min; longer exposure produces transesterification, discoloration, and a measurable drop in inherent viscosity. On a co-rotating twin-screw extruder with an L/D of 40:1, screw speed is typically set between 150 rpm and 250 rpm, and the temperature profile is zoned from 170°C at the feed throat to 200°C at the die. The extruder vent is maintained under vacuum to strip residual moisture and low-molecular-weight volatiles, but the vacuum port must not be so deep that it draws melt into the vent. For this specific grade, published production-scale data is limited; the settings above are to be verified by process qualification.

    If the melt temperature is set below 180°C, the grade may not homogenize sufficiently in the nozzle, producing visible flow lines and shrinkage anisotropy in small parts. If the melt is raised above 210°C, the risk shifts from incomplete filling to degradation; early signs are translucent amber discoloration and a reduction in inherent viscosity of more than 0.05 dL/g after a single pass. Batch-to-batch variation on a production line is usually traced to residual moisture or monomer content before molecular weight variation. When a lot exhibits lower melt viscosity at the same barrel settings, Karl Fischer analysis of the hopper feed and gas chromatography of the raw granulate are performed before adjusting the temperature profile. The melt viscosity of PURASORB PLG 8055 is intrinsically lower than that of a 1.0 dL/g grade, which is why the 0.55 dL/g material is preferred for injection moulding of small parts where thin flow paths and short cycle times are required.

    Incoming-Release Specifications and Compliance Markers for PURASORB PLG 8055

    The parameters in Table 1 are used as incoming-release markers for medical device polymer receipts; the manufacturer’s certificate of analysis remains the lot-specific source. Test methods are selected to align with chemical characterization expected under ISO 10993-1:2018 and ISO 10993-18:2020.

    Table 1. Typical incoming-release specification markers for PURASORB PLG 8055
    Parameter Typical specification Test method/standard
    Inherent viscosity 0.50–0.60 dL/g ISO 1628-1
    L-lactide/glycolide molar ratio 80:20 ± 2 mol% ¹H NMR; ISO 10993-18
    Residual monomers, total lactide and glycolide 0.5 wt% Gas chromatography; ISO 10993-18
    Residual solvent 0.1 wt% Headspace gas chromatography; ISO 10993-18
    Water content, Karl Fischer 0.5 wt% ISO 15512
    Sulfated ash 0.1 wt% ISO 3451-1
    Heavy metals, Pb, Cd, As, Hg, Co 10 ppm total ICP-MS; ISO 10993-18

    Biocompatibility of the finished device is not established by the polymer specification alone. The manufacturer supplies the polymer with a pre-screening suitability statement aligned to ISO 10993-1, but the device manufacturer must perform cytotoxicity, sensitization, irritation, and implantation testing on the final sterilized device according to ISO 10993-5, ISO 10993-10, and ISO 10993-6. Leachables evaluation under ISO 10993-18:2020 may include residual lactide, glycolide, and oligomeric degradation products; the analytical reporting threshold should be justified by the intended contact duration and tissue contact type.

    The principal differences between PURASORB PLG 8055 and other resorbable polyester grades lie in three independent variables: chain terminal group, lactide/glycolide ratio, and inherent viscosity. Table 2 summarizes the operational consequences. The comparisons are qualitative unless lot-specific test data are generated under the same conditions; published data for the exact product lot is limited, and the table is to be read as a differentiation framework rather than a degradation prediction.

    Table 2. Comparative processing and degradation differentiation for resorbable lactide-glycolide copolymers
    Variable PURASORB PLG 8055 Higher inherent viscosity 80:20 grade 50:50 PLG of similar inherent viscosity
    Monomer ratio 80:20 L-lactide/glycolide 80:20 L-lactide/glycolide 50:50 lactide/glycolide
    Terminal group Acid-capped Acid-capped Acid-capped
    Nominal inherent viscosity 0.55 dL/g 1.0 dL/g 0.55 dL/g
    Melt viscosity Lower; suited to injection moulding Higher; suited to extrusion or fibre spinning Similar to PURASORB PLG 8055
    Water uptake rate Intermediate Intermediate Higher
    Mass-loss onset Slower than 50:50; earlier than ester-capped 80:20 Slower due to higher chain length Fastest of the three
    Processing preference Small implants with thin flow paths Higher melt strength; thermally sensitive Rapid-resorbing devices or drug-delivery matrices

    When the design requires load-bearing fixation lasting beyond 12 weeks, the 80:20 grade is preferred over 50:50 under identical implant geometry and sterilization route. For matrices where rapid mass loss is desired, the 50:50 D,L-lactide/glycolide grade remains the typical benchmark. The acid-capped terminal group in PURASORB PLG 8055 should not be confused with lower molecular weight; acid capping alters degradation rate at constant chain length rather than simply reducing melt viscosity. Within the PURASORB portfolio, the PLG prefix denotes L-lactide-based copolymers, while PDLG grades contain D,L-lactide and are more amorphous. The stereochemical difference changes degradation behaviour and solvent-based processing characteristics; for melt processing, both classes can be run on similar equipment, but drying and storage limits must be verified for the specific grade.

    Terminal sterilization must be incorporated into device design verification because aliphatic polyesters are sensitive to ionizing radiation, heat, and moisture. Ethylene oxide processing under ISO 11135:2014 is the least hydrolytically aggressive terminal method for this polymer class, but the finished device must be assessed for residual ethylene oxide, ethylene chlorohydrin, and ethylene glycol according to ISO 10993-7:2008. Gamma irradiation under ISO 11137 is possible only if dose-setting establishes that the absorbed dose does not reduce inherent viscosity below the device design limit; absorbed doses above 25 kGy are typically associated with measurable chain scission in aliphatic polyesters, although the exact dose-response for this lot is not published. Steam sterilization is not recommended because the combination of heat and water accelerates hydrolysis. Dry-heat sterilization above the glass transition temperature is also not recommended because it can cause dimensional distortion and melt fusion of pellets. Package format must include a desiccant and an oxygen absorber when ethylene oxide is used, because residual moisture after sterilization can shorten the usable shelf life of the polymer.

    Reprocessing of devices is not recommended. Any regrind inclusion changes molar mass distribution and degradation predictability; the manufacturer’s medical-grade supply is not intended for direct substitution of virgin granulate by runners, sprues, or rejected parts. If regrind is used under controlled conditions, the maximum addition level must be established by verification of inherent viscosity and residual monomer content, not assumed from standard thermoplastics practice.

    Top